295 related articles for article (PubMed ID: 30416309)
1. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
Adinolfi LE; Rinaldi L; Nevola R
World J Gastroenterol; 2018 Nov; 24(41):4617-4621. PubMed ID: 30416309
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
3. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.
Mazzaro C; Quartuccio L; Adinolfi LE; Roccatello D; Pozzato G; Nevola R; Tonizzo M; Gitto S; Andreone P; Gattei V
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835054
[TBL] [Abstract][Full Text] [Related]
4. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection.
Mohanty A; Salameh S; Butt AA
Curr HIV/AIDS Rep; 2019 Oct; 16(5):389-394. PubMed ID: 31482299
[TBL] [Abstract][Full Text] [Related]
5. Extrahepatic manifestations of HCV.
Grignoli R; Goossens N; Negro F
Minerva Gastroenterol Dietol; 2015 Mar; 61(1):31-8. PubMed ID: 25390287
[TBL] [Abstract][Full Text] [Related]
6. Extrahepatic morbidity and mortality of chronic hepatitis C.
Negro F; Forton D; Craxì A; Sulkowski MS; Feld JJ; Manns MP
Gastroenterology; 2015 Nov; 149(6):1345-60. PubMed ID: 26319013
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic manifestations of HCV: the role of direct acting antivirals.
Polo ML; Laufer N
Expert Rev Anti Infect Ther; 2017 Aug; 15(8):737-746. PubMed ID: 28696154
[TBL] [Abstract][Full Text] [Related]
8. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
[TBL] [Abstract][Full Text] [Related]
9. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.
Salama II; Raslan HM; Abdel-Latif GA; Salama SI; Sami SM; Shaaban FA; Abdelmohsen AM; Fouad WA
World J Hepatol; 2022 Jun; 14(6):1053-1073. PubMed ID: 35978668
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus-Associated Cancers.
Yi Z; Yuan Z
Adv Exp Med Biol; 2017; 1018():129-146. PubMed ID: 29052135
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Manifestations of Hepatitis C Virus.
Goossens N; Negro F
Clin Liver Dis; 2017 Aug; 21(3):465-473. PubMed ID: 28689586
[TBL] [Abstract][Full Text] [Related]
13. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update.
Roguljic H; Nincevic V; Bojanic K; Kuna L; Smolic R; Vcev A; Primorac D; Vceva A; Wu GY; Smolic M
Front Pharmacol; 2021; 12():678546. PubMed ID: 34045969
[TBL] [Abstract][Full Text] [Related]
14. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.
Sagnelli E; Sagnelli C; Russo A; Pisaturo M; Camaioni C; Astorri R; Coppola N
Adv Exp Med Biol; 2021; 1323():115-147. PubMed ID: 33326112
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C and Its Metabolic Complications in Kidney Disease.
Fabrizi F; Donato FM; Messa P
Ann Hepatol; 2017 November-December,; 16(6):851-861. PubMed ID: 29055921
[TBL] [Abstract][Full Text] [Related]
16. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
Adinolfi LE; Petta S; Fracanzani AL; Coppola C; Narciso V; Nevola R; Rinaldi L; Calvaruso V; Staiano L; Di Marco V; Marrone A; Pafundi PC; Solano A; Lombardi R; Sasso FC; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A
Atherosclerosis; 2020 Mar; 296():40-47. PubMed ID: 32005004
[TBL] [Abstract][Full Text] [Related]
17. [Selection of direct-acting antiviral agents for chronic hepatitis C infection].
He YJ; Liu ZH; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):169-172. PubMed ID: 29804388
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.
Wiznia LE; Laird ME; Franks AG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1260-1270. PubMed ID: 28252812
[TBL] [Abstract][Full Text] [Related]
19. Extrahepatic manifestations in chronic hepatitis C virus carriers.
Rosenthal E; Cacoub P
Lupus; 2015 Apr; 24(4-5):469-82. PubMed ID: 25801890
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management.
Nevola R; Acierno C; Pafundi PC; Adinolfi LE
Minerva Med; 2021 Apr; 112(2):188-200. PubMed ID: 33205641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
